Peptides from the Variable Region of Specific Antibodies Are Shared among Lung Cancer Patients

Dominique Costa, Ingrid Broodman, W Calame, Christoph Stingl, Lennard Dekker, René Vernhout, Harry de Koning, Henk Hoogsteden, Peter Sillevis Smitt, RJ Klaveren, Theo Luider, MM VanDuijn

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
3 Downloads (Pure)

Abstract

Late diagnosis of lung cancer is still the main reason for high mortality rates in lung cancer. Lung cancer is a heterogeneous disease which induces an immune response to different tumor antigens. Several methods for searching autoantibodies have been described that are based on known purified antigen panels. The aim of our study is to find evidence that parts of the antigen-binding-domain of antibodies are shared among lung cancer patients. This was investigated by a novel approach based on sequencing antigen-binding-fragments (Fab) of immunoglobulins using proteomic techniques without the need of previously known antigen panels. From serum of 93 participants of the NELSON trial IgG was isolated and subsequently digested into Fab and Fc. Fab was purified from the digested mixture by SDS-PAGE. The Fab containing gel-bands were excised, tryptic digested and measured on a nano-LC-Orbitrap-Mass-spectrometry system. Multivariate analysis of the mass spectrometry data by linear canonical discriminant analysis combined with stepwise logistic regression resulted in a 12-antibody-peptide model which was able to distinguish lung cancer patients from controls in a high risk population with a sensitivity of 84% and specificity of 90%. With our Fab-purification combined Orbitrap-mass-spectrometry approach, we found peptides from the variable-parts of antibodies which are shared among lung cancer patients.
Original languageUndefined/Unknown
JournalPLoS One (print)
Volume9
Issue number5
DOIs
Publication statusPublished - 2014

Cite this